An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

NCT06013475 · clinicaltrials.gov ↗

COMPLETED

Status

1375

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Apalutamide
DRUG: Darolutamide (BAY 1841788)
DRUG: Enzalutamide

Sponsor

Bayer